WST Lead Plaintiff Deadline Approaching – WST Stockholders Should Contact Robbins LLP for Information About Leading the West Pharmaceutical Services, Inc. Class Action Lawsuit

Core Viewpoint - A class action lawsuit has been filed against West Pharmaceutical Services, Inc. for allegedly misleading investors about the company's business prospects during the period from February 16, 2023, to February 12, 2025 [1][2]. Allegations - The lawsuit claims that West Pharmaceutical failed to disclose significant ongoing destocking in its high-margin HVP portfolio, contrary to its assertions of strong customer demand [2]. - It is alleged that the SmartDose device, marketed as a high-margin growth product, was actually dilutive to profit margins due to operational inefficiencies [2]. - The margin pressures faced by the company raised the risk of costly restructuring activities, including exiting continuous glucose monitoring contracts with long-standing customers [2]. - Positive statements made by the company regarding its business and prospects were claimed to be materially false or misleading [2]. Disclosure of Truth - The truth about the alleged fraud was revealed on February 13, 2025, when West issued weak revenue and earnings forecasts for 2025, attributing the disappointing guidance to the loss of two major CGM customers transitioning to in-house manufacturing [3]. - West also indicated that its SmartDose devices would be margin dilutive in 2025 and mentioned that steps would be taken to improve the economics of the SmartDose [3]. - Following this announcement, West's stock price fell by $123.17 per share, a decline of approximately 38%, closing at $199.11 on February 13, 2025 [3]. Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 7, 2025 [4]. - Shareholders can remain absent class members and still be eligible for recovery without participating in the case [4]. About Robbins LLP - Robbins LLP is recognized for its work in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].